GYKI 52466

GYKI 52466
GYKI 52466
Skeletal formula
Space-filling model of GYKI-52,466
이름
선호 IUPAC 이름
4-(8-메틸-2H,9H-[1,3]다이옥솔로[4,5-h][2,3]벤조디아제핀-5-yl)아닐린
식별자
3D 모델(JSmol)
체비
켐벨
켐스파이더
ECHA InfoCard 100.162.378 Edit this at Wikidata
케그
펍켐 CID
유니
  • InChI=1S/C17H15N3O2/c1-10-6-12-7-15-16(22-9-21-15)8-14(12)17(20-19-10)11-2-4-13(18)5-3-11/h2-5,7-8H,6,9,18H2,1H3 ☒N
    키: LFBZZHVSGAHQPP-UHFFFAOYSA-N ☒N
  • InChi=1/C17H15N3O2/c1-10-6-12-7-15-16(22-9-21-15)8-14-17(20-19-10)11-2-4-13(18)11-2-4-13(18)11-2-5,7-8H,6,9,18H2,1H2,1H3
    키: LFBZZHVSGAHQPP-UHFFFAOYAH
  • CC1=NN=C(C2=CC3=C(C=C2C1)OCO3)C4=CC=C(C=C4)n
특성.
C17H15N3O2
어금질량 293.326 g·190−1
외관 황색 고체(HCL 소금)
밀도 1.393 g/cm3
>10 mg/mL (HCl 소금)
달리 명시된 경우를 제외하고, 표준 상태(25°C [77°F], 100 kPa)의 재료에 대한 데이터가 제공된다.
☒ NVERIFI (?란checkY☒N?

GYKI 52466 is a 2,3-benzodiazepine that acts as an ionotropic glutamate receptor antagonist, which is a non-competitive AMPA receptor antagonist (IC50 values are 10-20, ~ 450 and >> 50 μM for AMPA-, kainate- and NMDA-induced responses respectively), orally-active anticonvulsant, and skeletal muscle relaxant.[1][2][3][4]기존 1,4-벤조디아제핀과 달리 GYKI 52466 및 관련 2,3-벤조디아제핀은 GABAA 수용체에 작용하지 않는다.[5]다른 AMPA 수용체 길항제들과 마찬가지로 GYKI 52466에도 항경련성 및 신경보호성이 있다.[6]

참고 항목

참조

  1. ^ Donevan, S.D; Rogawski, M.A (1998). "Allosteric regulation of α-amino-3-hydroxy-5-methyl-4-isoxazole-propionate receptors by thiocyanate and cyclothiazide at a common modulatory site distinct from that of 2,3-benzodiazepines". Neuroscience. 87 (3): 615–629. doi:10.1016/s0306-4522(98)00109-2. PMID 9758228. S2CID 14817743.
  2. ^ Donevan, Sean D.; Rogawski, Michael A. (1993). "GYKI 52466, a 2,3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/Kainate receptor responses". Neuron. 10 (1): 51–59. doi:10.1016/0896-6273(93)90241-i. PMID 7678966. S2CID 16011527.
  3. ^ Tarnawa, István; Farkas, Sándor; Berzsenyi, Pál; Pataki, Ágnes; Andrási, Ferenc (1989). "Electrophysiological studies with a 2,3-benzodiazepine muscle relaxant: GYKI 52466". European Journal of Pharmacology. 167 (2): 193–199. doi:10.1016/0014-2999(89)90579-7. PMID 2574112.
  4. ^ Rzeski, W.; Turski, L.; Ikonomidou, C. (2001). "Glutamate antagonists limit tumor growth". Proceedings of the National Academy of Sciences. 98 (11): 6372–6377. doi:10.1073/pnas.091113598. PMC 33475. PMID 11331750.
  5. ^ Paternain, Ana V.; Morales, Miguel; Lerma, Juan (1995). "Selective antagonism of AMPA receptors unmasks kainate receptor-mediated responses in hippocampal neurons". Neuron. 14 (1): 185–189. doi:10.1016/0896-6273(95)90253-8. PMID 7826635. S2CID 6037517.
  6. ^ Szabados, Tamás; Gigler, Gábor; Gacsályi, István; Gyertyán, István; Lévay, György (2001). "Comparison of anticonvulsive and acute neuroprotective activity of three 2,3-benzodiazepine compounds, GYKI 52466, GYKI 53405, and GYKI 53655". Brain Research Bulletin. 55 (3): 387–391. doi:10.1016/s0361-9230(01)00516-0. PMID 11489346. S2CID 23142293.